Sarepta Therapeutics今日宣布与Arrowhead ...

InvestingPro提示强调，Dyne Therapeutics预计今年将不会盈利，这与公司目前的发展阶段和在基因医学领域的大量研发投资相符。然而，分析师预测该公司将在2年内实现盈利，这表明随着其开创性技术的进展，可能会出现潜在的转机。

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...

RNA therapeutics promise rapid, personalized and flexible treatments against multiple diseases. In this article, we will ...

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "North America RNA Therapeutics Market, By Country, Competition, Forecast & ...

The 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stock into one new share of common stock. No fractional shares will be issued in ...

In a report released on November 22, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on PYC Therapeutics Limited (PYC – Research ...

ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the Kennedy's ...

2024年11月19日，中美瑞康（Ractigen Therapeutics）宣布其自主研发的FUS基因靶向小干扰RNA（siRNA）疗法RAG-21，成功获得美国食品药品监督管理局（FDA）授予的孤儿药资格（Orphan Drug ...

制药公司Ractigen Therapeutics宣布，美国食品药品管理局 (FDA) 已授予 RAG-21 “孤儿药认定” (Orphan Drug Designation, ODD)资格 ，该药物是一种靶向FUS基因的新型 siRNA 疗法，用于治疗肌萎缩性脊髓侧索硬化症 (ALS)。 制药公司Ractigen Therapeutics 11月中旬宣布，美国食品药品管理局 (FDA) 已授予 ...